Targeted cell therapy for relapsed B-cell cancer
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new kind of cell therapy where your own immune cells are turned into cancer-fighting cells (CAR-T cells) that target a protein called CD19 or BAFF-R on your B-cell leukemia or lymphoma cells. It is for people whose cancer has not gotten better with standard treatments or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell acute leukemia or B-cell lymphoma that has not responded to treatment or has come back.
- Your cancer cells show a marker called CD19 or BAFF-R on a lab test.
- You are between 14 and 75 years old.
- Your general health is reasonably good (ECOG score 0–3, meaning you can do at least some daily activities).
- Your heart, kidneys, and lungs work well enough for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a locally made CAR T-cell therapy that targets CD19 on cancer cells. It is for children and young adults with certain B-cell cancers that have come back or not responded to other treatments.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new treatment using your own immune cells that are modified to find and kill cancer cells in the blood or lymph nodes. It's for people whose leukemia or lymphoma has come back or did not go away after previous treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.